Announcements Trials
Browse Landscape

Status

No longer available 2Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 86Observational 6Expanded_access 3

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Lymphangioma 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Alpelisib × Clear all
NCT04085653 2026-04-14

Managed Access Programs for BYL719, Alpelisib

Novartis

Available
Breast

Breast Neoplasms

NCT03941782 2024-01-11

Compassionate Use of BYL 719 Alpelisib

New Mexico Cancer Research Alliance

No longer available

Lymphangioma

NCT03706573 2021-07-19

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Novartis

No longer available
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡